Physician profile
Curtis M Wright
NPI 1053450510
$6,338.05
in general payments reported to CMS, 2019-2025
26 companies · $1,467 in 2025
The $1,467 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $814 · 2022: $1,431 · 2023: $1,236 · 2024: $1,390 · 2025: $1,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,918 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,917.72 |
| Education | $174.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,724.08 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $1,143.39 | 2021-2025 | |
| Glaxosmithkline, LLC. | $987.76 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $521.02 | 2021-2025 | Dupixent |
| Amgen INC. | $390.76 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $307.73 | 2022-2025 | |
| Optinose US, INC. | $241.30 | 2021-2025 | |
| Kaleo, INC. | $141.64 | 2021-2023 | Auvi-Q |
| Pfizer INC. | $125.65 | 2021-2024 | |
| Grifols USA, LLC | $115.01 | 2024-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $101.81 | 2021-2025 | Takhzyro, Cuvitru |
| Pharming Healthcare, INC. | $83.68 | 2023-2024 | Ruconest |
| Sanofi-Aventis U.S. LLC | $83.00 | 2023 | |
| Mylan Specialty L.P. | $78.37 | 2021-2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $39.22 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $33.88 | 2022-2024 | Adbry |
| Eyevance Pharmaceuticals LLC | $33.51 | 2021 | |
| Biocryst US Sales Co., LLC | $31.12 | 2024 | Orladeyo |
| Ars Pharmaceuticals Operations, INC. | $26.50 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $25.95 | 2021 | |
| Genentech USA, INC. | $20.11 | 2022 | |
| Csl Behring | $18.76 | 2025 | Andembry |
| Aimmune Therapeutics, INC. | $18.27 | 2021 | |
| Galderma Laboratories, L.P. | $17.21 | 2025 | Nemluvio |
| Azurity Pharmaceuticals, INC. | $14.73 | 2025 | Alvesco |
| Hikma Pharmaceuticals USA | $13.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.